- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01349335
Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200001
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites
- Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);
- During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;
- Ages: ≥18 and ≤75 years of age;
- Genders: men or women;
- Signed the Informed Consent Form.
Exclusion Criteria:
Patients with the following diseases, complications or symptoms:
- Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);
- Malignant ascites;
- Uncontrolled spontaneous bacterial peritonitis;
- Patients are likely to experience alimentary tract hemorrhage during the trial;
- Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4);
- Anuria (daily urine volume below 100mL);
- Dysuria resulting from urethral stricture, calculus and tumors.
Patients with the following medical history:
- Alimentary tract hemorrhage within 10 days prior to screening;
- Cerebrovascular accident within 1 month prior to screening;
- Gout attack within 1 month prior to screening;
- Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)
- Systolic pressure below 90mmHg at screening;
Patients with the following abnormalities in laboratory examinations at screening:
Serum creatinine exceeds 2.5X upper limits of normal, serum Na+>145mmol/L (or exceeds upper limits of normal), serum K+>5.5mmol/L, uric acid>8.0mg/dL (476μmol/L), Child-pugh scale greater than 12.
- Patients cannot take drugs orally;
- Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable contraceptive measures;
- Patients received albumin or other blood preparations within 4 days prior to trial drug administration;
- Patients participated in clinical trials of other drugs within 1 month prior to screening;
- Patients participated in tolvaptan trials and took tolvaptan previously;
- Patients are unsuitable to participate in this trial in investigators' opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1. tolvaptan
15 mg, P.O., Qd, for 7 days,
|
tablet, 15 mg, Qd, for 7 days
Other Names:
tablet, 30 mg, Qd, 7 days
Other Names:
|
Experimental: 2 tolvaptan
30 mg, P.O., Qd, for 7 days,
|
tablet, 15 mg, Qd, for 7 days
Other Names:
tablet, 30 mg, Qd, 7 days
Other Names:
|
Experimental: 3. Placebo
30mg,P.O.,Qd, for 7 days.
|
tablet, 30 mg, Qd, 7days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body weight changes after 7 days of treatment (quantity of changes)
Time Frame: from day1 to day7
|
from day1 to day7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body weight change after 4 days of treatment (quantity of changes)
Time Frame: from day1 to day4
|
from day1 to day4
|
Waist circumference after 4 and 7 days of treatment (quantity and rate of changes)
Time Frame: from day1 to day7
|
from day1 to day7
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-08-804-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ascites
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Sichuan Clover Biopharmaceuticals, Inc.Completed
-
Healthgen Biotechnology Corp.Completed
-
Sequana Medical N.V.CompletedMalignant AscitesGermany, Switzerland, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Terminated
-
MovetisCompleted
-
Postgraduate Institute of Medical Education and...UnknownRefractory Ascites
-
University of AlbertaBecton, Dickinson and CompanyCompleted
-
Eastern Regional Medical CenterTerminatedMalignant AscitesUnited States
-
Mansoura UniversityCompleted
Clinical Trials on Tolvaptan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)United States, United Kingdom, Belgium, Poland, France, Germany, Italy
-
Regional Hospital HolstebroAarhus University HospitalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
NYU Langone HealthWithdrawnSIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic OsmostatUnited States
-
Eli Lilly and CompanyActive, not recruitingPlaque Psoriasis | Psoriatic ArthritisIndia
-
Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney, Autosomal DominantJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
University of North Carolina, Chapel HillOtsuka America PharmaceuticalCompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States